(Q44879839)

7 December 2017

title

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma (English)

1 reference

7 December 2017

main subject

phase II clinical trial

0 references

author name string

Susan Burdette-Radoux

1 reference

7 December 2017

Richard G Tozer

1 reference

7 December 2017

Reinhard C Lohmann

1 reference

7 December 2017

Ian Quirt

1 reference

7 December 2017

D Scott Ernst

1 reference

7 December 2017

Wendy Walsh

1 reference

7 December 2017

Nancy Wainman

1 reference

7 December 2017

A Dimitrios Colevas

1 reference

7 December 2017

Elizabeth A Eisenhauer

1 reference

7 December 2017

publication date

1 August 2004

1 reference

Investigational New Drugs

7 December 2017

published in

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

315-322

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 December 2017

cites work

1 reference

12 December 2020

Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

12 December 2020

Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol

1 reference

12 December 2020

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

12 December 2020

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells

1 reference

12 December 2020

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

12 December 2020

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

12 December 2020

Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.

1 reference

12 December 2020

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

12 December 2020

Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.

1 reference

12 December 2020

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

1 reference

12 December 2020

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

1 reference

12 December 2020

Expression of cell cycle regulators in human cutaneous malignant melanoma

1 reference

12 December 2020

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

12 December 2020

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

12 December 2020

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

12 December 2020

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

1 reference

12 December 2020

10.1023/B:DRUG.0000026258.02846.1C

Identifiers

DOI

1 reference

Dimensions Publication ID

7 December 2017

1012390955

0 references

1 reference